


or



; or a pharmaceutically acceptable salt or solvate thereof.

[0012] In another embodiment is a pharmaceutical composition comprising a compound of Formula (I), (A), or (B) described herein, or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient.

[0013] In another embodiment is a method of treating pain in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (A), or (B) described herein, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pain is neuropathic pain. In some embodiments, the pain is inflammatory pain.

[0013a] In another aspect, described herein is a compound as described herein or a pharmaceutically acceptable salt or solvate thereof for use in therapy.

[0013b] In another aspect, described herein is a use of a compound as described herein, or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for treating pain in a patient.

[0014] In another embodiment is a method of treating a disease or disorder in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (A), or (B) described herein, or a pharmaceutically acceptable salt or solvate thereof, wherein the disease or disorder is selected from the group consisting of epilepsy/seizure disorder, multiple sclerosis, neuromyelitis optica (NMO), Tourette syndrome, Alzheimer's disease, and abdominal pain associated with irritable bowel syndrome. In some embodiments, the disease or disorder is epilepsy/seizure disorder. In some embodiments, the disease or disorder is multiple sclerosis. In some embodiments, the disease or disorder is neuromyelitis optica (NMO). In some embodiments, the disease or disorder is Tourette syndrome. In some embodiments, the disease or disorder is Alzheimer's disease. In some embodiments, the disease or disorder is abdominal pain associated with irritable bowel syndrome.

[0014a] In another aspect, described herein is a use of a compound as described herein, or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for treating a disease or disorder in a patient, wherein the disease or disorder is selected from

the group consisting of epilepsy/seizure disorder, multiple sclerosis, neuromyelitis optica (NMO), Tourette syndrome, Alzheimer's disease, and abdominal pain associated with irritable bowel syndrome.

DETAILED DESCRIPTION OF THE INVENTION


[0015] This disclosure is directed, at least in part, to compounds capable of inhibiting MAGL.

[0016] As used herein and in the appended claims, the singular forms "a," "and," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an agent" includes a plurality of such agents, and reference to "the cell" includes reference to one or more cells (or to a plurality of cells) and equivalents thereof. When ranges are used herein for physical properties, such as molecular weight, or chemical

CLAIMS

We Claim:

1. A compound having the structure of Formula (I):



Formula (I);

wherein:

R^1 is $-N(R^3)(R^5)$ or $-NH(R^4)$;

each R^2 is independently selected from halogen, C_{1-6}alkyl, -CN, C_{1-6}haloalkyl, and $-OR^6$;

R^3 is $-CH_2CO_2H$, $-CH_2CH_2CO_2H$, or $-CH(CH_3)CO_2H$;

R^4 is $-(CH_2)_m-CO_2H$;

R^5 is H or C_{1-3}alkyl;

each R^6 is independently selected from H, C_{1-6}alkyl, and C_{1-6}haloalkyl;


n is 0, 1, 2, 3, or 4; and

m is 3;

or a pharmaceutically acceptable salt or solvate thereof.

2. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein R^1 is $-N(R^3)(R^5)$.
3. The compound of claim 2, or a pharmaceutically acceptable salt or solvate thereof, wherein R^5 is H.
4. The compound of claim 2, or a pharmaceutically acceptable salt or solvate thereof, wherein R^5 is C_{1-3}alkyl.
5. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt or solvate thereof, wherein R^3 is $-CH_2CO_2H$.
6. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt or solvate thereof, wherein R^3 is $-CH_2CH_2CO_2H$.
7. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt or solvate thereof, wherein R^3 is $-CH(CH_3)-CO_2H$.
8. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein R^1 is $-NH(R^4)$.

9. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt or solvate thereof, wherein each R^2 is independently selected from halogen, C_{1-6}alkyl, and C_{1-6}haloalkyl.
10. The compound of claim 9, or a pharmaceutically acceptable salt or solvate thereof, wherein R^2 is halogen.
11. The compound of claim 10, or a pharmaceutically acceptable salt or solvate thereof, wherein R^2 is -Cl.
12. The compound of claim 9, or a pharmaceutically acceptable salt or solvate thereof, wherein R^2 is C_{1-6}haloalkyl.
13. The compound of claim 12, or a pharmaceutically acceptable salt or solvate thereof, wherein R^2 is $-CF_3$.
14. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1.
15. A compound having the structure of Formula (A):



Formula (A);

wherein:

R^1 is hydrogen or deuterium;

each R^2, R^3, R^4, and R^5 is deuterium;

n is 0, 1, 2, 3, 4, 5, 6, 7, or 8;

p is 0, 1, or 2;

q is 0, 1, 2, or 3; and


t is 0, 1, 2, 3, 4, 5, 6, 7, or 8;

wherein when R^1 is hydrogen, then at least one of n, p, q, and t is not 0;

or a pharmaceutically acceptable salt or solvate thereof.

16. The compound of claim 15, or a pharmaceutically acceptable salt or solvate thereof, wherein R^1 is deuterium.
17. The compound of claim 15, or a pharmaceutically acceptable salt or solvate thereof, wherein R^1 is hydrogen.

18. The compound of any one of claims 15-17, or a pharmaceutically acceptable salt or solvate thereof, wherein p is 0, q is 0, and t is 0.
19. The compound of any one of claims 15-17, or a pharmaceutically acceptable salt or solvate thereof, wherein n is 0, p is 0, and q is 0.
20. A compound having the structure of Formula (B):



Formula (B);

wherein:

R^1 is hydrogen or deuterium;

each R^2, R^3, and R^4 is deuterium;

each R^5 is independently hydrogen or deuterium;

n is 0, 1, 2, 3, 4, 5, 6, 7, or 8;








p is 0, 1, or 2; and

q is 0, 1, 2, or 3;



wherein when R^1 is hydrogen, then at least one of n, p, and q is not 0, or at least one R^5 is deuterium;

or a pharmaceutically acceptable salt or solvate thereof.

21. The compound of claim 20, or a pharmaceutically acceptable salt or solvate thereof, wherein R^1 is deuterium.
22. The compound of claim 20, or a pharmaceutically acceptable salt or solvate thereof, wherein R^1 is hydrogen.
23. The compound of any one of claims 20-22, or a pharmaceutically acceptable salt or solvate thereof, wherein p is 0, q is 0, and each R^5 is hydrogen.
24. The compound of any one of claims 20-22, or a pharmaceutically acceptable salt or solvate thereof, wherein n is 0, p is 0, and q is 0.
25. A compound having the structure selected from:


,

,

,

,

,

, and

; or a pharmaceutically acceptable salt or solvate thereof.

26. A compound having the structure:


or

; or a pharmaceutically acceptable salt or solvate thereof.

27. A pharmaceutical composition comprising a compound of any one of claims 1-26, or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient.

28. The compound of any one of claims 1-26, or a pharmaceutically acceptable salt or solvate thereof for use in therapy.
29. Use of a compound of any one of claims 1-26, or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for treating pain in a patient.
30. The use of claim 29, wherein the pain is neuropathic pain.
31. The use of claim 29, wherein the pain is inflammatory pain.
32. Use of a compound of any one of claims 1-26, or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for treating a disease or disorder in a patient, wherein the disease or disorder is selected from the group consisting of epilepsy/seizure disorder, multiple sclerosis, neuromyelitis optica (NMO), Tourette syndrome, Alzheimer's disease, and abdominal pain associated with irritable bowel syndrome.
33. The use of claim 32, wherein the disease or disorder is epilepsy/seizure disorder.
34. The use of claim 32, wherein the disease or disorder is multiple sclerosis.
35. The use of claim 32, wherein the disease or disorder is neuromyelitis optica (NMO).
36. The use of claim 32, wherein the disease or disorder is Tourette syndrome.
37. The use of claim 32, wherein the disease or disorder is Alzheimer's disease.
38. The use of claim 32, wherein the disease or disorder is abdominal pain associated with irritable bowel syndrome.